Advertisement
BDX vs MMSI
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. Merit Medical Systems (MMSI) Stock Comparison
Key Takeaways
- BDX is a large-cap medical technology leader recently transformed into a focused, pure-play "New BD" after spinning off its Life Sciences business.
- MMSI is a mid-cap interventional device maker delivering accelerating organic growth and margin expansion through disciplined tuck-in acquisitions.
- Tickeron AI Verdict: Based on trend consistency, lower volatility, and durable growth catalysts, the AI framework currently leans toward BDX over MMSI, while acknowledging MMSI's stronger growth rate.
- BDX's relative performance has been steadier and less volatile, supported by strong free cash flow and shareholder returns; MMSI has posted sharper momentum but faces a higher valuation premium and tariff sensitivity.
- Explore further coverage of BDX Major News and BDX Today's Price Move, as well as MMSI Major News and MMSI Today's Price Move, for ongoing updates on each ticker.
- To see how AI trading systems are positioning across these and other names, explore Trending AI Robots.
Introduction
Becton, Dickinson and Company (BDX) and Merit Medical Systems (MMSI) both operate in the medical technology sector, yet they occupy very different positions within it. BDX is a diversified, large-cap leader spanning drug delivery, diagnostics, and interventional care, while MMSI is a mid-cap specialist in single-use interventional and therapeutic devices. This stock comparison is relevant for investors weighing scale and stability against faster growth and margin expansion. By examining recent market activity, business models, and relative performance, this analysis aims to clarify how each company's market positioning has evolved and which name an AI-driven framework would currently favor.
BDX Overview and Recent Performance
BDX, commonly known as BD, is one of the world's largest medical technology companies, with a portfolio spanning connected care, interventional products, biopharma drug delivery systems, and medical essentials. A defining development in recent months was the completion of the spin-off of its Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation, leaving a more focused "New BD" oriented toward faster-growing MedTech platforms.
Recent market activity has reflected improving execution. In its most recent fiscal quarters, BDX reported revenue growth in the low-to-mid single digits on a currency-neutral basis and raised its full-year adjusted earnings per share (EPS) outlook, citing broad-based portfolio strength. More than 90% of the portfolio has been growing, with double-digit gains in platforms such as biologic drug delivery, advanced patient monitoring, PureWick, and advanced tissue regeneration. Sentiment has also been supported by strong free cash flow generation, accelerated share repurchases, and a major U.S. manufacturing investment framework. Offsetting these positives are defined headwinds, including the Alaris infusion system remediation, soft vaccine demand in China, and tariff-related margin pressure.
MMSI Overview and Recent Performance
MMSI, Merit Medical Systems, designs, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, organized around cardiovascular and endoscopy segments. The company has built its growth profile on steady procedure volumes, a multi-year efficiency program, and disciplined "tuck-in" acquisitions that fill product gaps.
In recent weeks, MMSI has reported accelerating organic revenue growth of roughly 9% on a constant-currency basis, with notable strength in its faster-growing therapeutic products, including cardiac therapies and endoscopy. Non-GAAP operating margin (a measure of profitability that excludes certain one-time items) expanded significantly year over year, and adjusted EPS rose by a double-digit percentage. Management raised full-year guidance after a beat-and-raise quarter and added to its cardiac portfolio with the acquisition of Solo Pace, which provides pacing technology used in transcatheter aortic valve replacement (TAVR, a minimally invasive heart valve procedure). Offsetting factors include tariff costs, a competitive interventional market, and some volatility in international demand, including China volume-based purchasing dynamics.
Trending AI Robots
Tickeron operates a marketplace of hundreds of AI Trading Bots that trade thousands of different tickers across a range of styles, strategies, timeframes, and performance profiles. Because market conditions change continuously, only a select subset of these bots is well suited to the current environment at any given time. That is the purpose of the Trending AI Robots section, a curated list highlighting the systems whose statistical profiles and recent performance make them most relevant right now. Each bot differs in the tickers it trades, its risk parameters, and its approach to entry and exit signals. Exploring this section can help traders and investors understand how AI-driven frameworks are currently positioning across names like BDX and MMSI.
Head-to-Head Comparison
While both companies compete in medical technology, their market positioning differs sharply. BDX offers scale, diversification, and a lower beta (a measure of volatility relative to the broader market), which historically implies a more stable trading profile. Its catalysts center on portfolio focus, innovation in drug delivery, and capital returns. MMSI, by contrast, offers a higher organic growth rate and expanding margins, but carries a smaller revenue base, a premium valuation relative to its peer group, and greater sensitivity to tariffs and procedure-volume swings.
In terms of recent momentum, MMSI has delivered sharper share-price appreciation over the past several months but also exhibited a post-earnings pullback, a reminder of its higher near-term volatility. BDX has trended higher more consistently and currently trades near its 52-week high. Risk factors also differ: BDX faces a defined Alaris remediation headwind and China vaccine softness, while MMSI faces integration risk from acquisitions, competitive pricing pressure, and reimbursement considerations. From a sector-exposure standpoint, BDX is more diversified across medtech categories, whereas MMSI is more concentrated in interventional and endoscopic devices.
Tickeron AI Verdict
Weighing the observable factors, the AI framework's current preference tilts toward BDX. The rationale rests on a steadier and more consistent uptrend, lower volatility as reflected in a notably lower beta, and multiple durable catalysts, including strong free cash flow, aggressive capital returns, and a focused post-spin portfolio. MMSI's faster organic growth and margin expansion are genuine strengths, but its sharper post-earnings volatility and higher valuation premium introduce greater near-term trend uncertainty. As a result, while both names demonstrate fundamentally solid positioning, the probabilistic AI assessment favors BDX for trend consistency and relative stability, without dismissing MMSI's long-term growth potential.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a Buy and MMSI is a Buy.
BDX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BDX turned positive on October 09, 2026. Looking at past instances where BDX's MACD turned positive, the stock continued to rise in 26 of 45 cases over the following month. The odds of a continued upward trend are 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BDX as a result. In 54 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
BDX moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BDX crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +7.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDX advanced for three days, in 134 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
The Aroon Indicator entered an Uptrend today. In 114 of 218 cases where BDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
BDX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. BDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.364) is normal, around the industry mean (4.964). P/E Ratio (63.819) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.107) is also within normal values, averaging (4.143). BDX has a moderately high Dividend Yield (0.020) as compared to the industry average of (0.005). P/S Ratio (2.290) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
MMSI sees its Stochastic Oscillator ascending out of oversold territory
On November 05, 2026, the Stochastic Oscillator for MMSI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 41 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
MMSI moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MMSI crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 47%.
Following a +3.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where MMSI advanced for three days, in 198 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
MMSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for MMSI moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 25 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MMSI as a result. In 55 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.
The Moving Average Convergence Divergence Histogram (MACD) for MMSI turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 18 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. MMSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.101) is normal, around the industry mean (4.964). P/E Ratio (35.604) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.574) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.273) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
BDX | MMSI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 38 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 59 | 76 | |
SMR RATING 1..100 | 85 | 74 | |
PRICE GROWTH RATING 1..100 | 3 | 43 | |
P/E GROWTH RATING 1..100 | 5 | 74 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MMSI's Valuation (73) in the Medical Specialties industry is in the same range as BDX (75). This means that MMSI’s stock grew similarly to BDX’s over the last 12 months.
BDX's Profit vs Risk Rating (59) in the Medical Specialties industry is in the same range as MMSI (76). This means that BDX’s stock grew similarly to MMSI’s over the last 12 months.
MMSI's SMR Rating (74) in the Medical Specialties industry is in the same range as BDX (85). This means that MMSI’s stock grew similarly to BDX’s over the last 12 months.
BDX's Price Growth Rating (3) in the Medical Specialties industry is somewhat better than the same rating for MMSI (43). This means that BDX’s stock grew somewhat faster than MMSI’s over the last 12 months.
BDX's P/E Growth Rating (5) in the Medical Specialties industry is significantly better than the same rating for MMSI (74). This means that BDX’s stock grew significantly faster than MMSI’s over the last 12 months.
| BDX | MMSI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 63% | 1 day ago 66% |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 53% | 1 day ago 59% |
| MACD ODDS (%) | 1 day ago 58% | 1 day ago 50% |
| TrendWeek ODDS (%) | 1 day ago 50% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 52% | 1 day ago 58% |
| Advances ODDS (%) | 6 days ago 46% | 20 days ago 66% |
| Declines ODDS (%) | 15 days ago 42% | 5 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 51% | 1 day ago 64% |
| Aroon ODDS (%) | 1 day ago 52% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 2 FA rating(s) are green while MMSI’s FA Score has 0 green FA rating(s).
- BDX’s FA Score: 2 green, 3 red.
- MMSI’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 6 TA indicator(s) are bullish while MMSI’s TA Score has 5 bullish TA indicator(s).
- BDX’s TA Score: 6 bullish, 4 bearish.
- MMSI’s TA Score: 5 bullish, 4 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +8.38% price change this week, while MMSI (@Pharmaceuticals: Other) price change was +4.87% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.53%. For the same industry, the average monthly price growth was +4.73%, and the average quarterly price growth was +18.71%.
Reported Earning Dates
BDX is expected to report earnings on Feb 04, 2027.
MMSI is expected to report earnings on Feb 24, 2027.
Industries' Descriptions
@Pharmaceuticals: Other (+5.53% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
MMSI and
Correlation & Price change
A.I.dvisor indicates that over the last year, MMSI has been loosely correlated with BSX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MMSI jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To MMSI | 1D Price Change % | ||
|---|---|---|---|---|
| MMSI | 100% | +1.36% | ||
| BSX - MMSI | 56% Loosely correlated | +2.97% | ||
| SYK - MMSI | 50% Loosely correlated | -0.04% | ||
| ICUI - MMSI | 50% Loosely correlated | +3.92% | ||
| ISRG - MMSI | 48% Loosely correlated | +1.71% | ||
| COO - MMSI | 44% Loosely correlated | +2.52% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| KTUP | 2.94 | 0.36 | +13.95% |
| T-REX 2X Long KTOS Daily Target ETF (KTUP) | |||
| DSMC | 44.96 | 0.94 | +2.14% |
| Distillate Small/Mid Cash Flow ETF (DSMC) | |||
| HYMB | 24.34 | -0.02 | -0.08% |
| State Street SPDR Nuveen ICE High Yield Municipal Bond ETF (HYMB) | |||
| RFIX | 36.15 | -0.50 | -1.36% |
| Simplify Downside Interest Rate Hedge Strategy ETF | |||
| MSTU | 24.50 | -1.31 | -5.08% |
| T-Rex 2X Long MSTR Daily Target ETF (MSTU) | |||